Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23678862 | 0.85 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL21870722 | 0.84 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL21870721 | 0.84 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL4065426 | 0.83 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL2236505 | 0.80 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL16611566 | 0.75 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL31233487 | 0.74 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL4064444 | 0.74 | ADORA2A (0.33) | — | |
| SCHEMBL30240072 | 0.73 | CYP1A2 (0.44) | — | |
| SCHEMBL16610937 | 0.72 | DGAT1 (0.40) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2077268-A1 | Process for preparing inhibitors of nucleoside metabolism | Industrial Research Limited (NZ) | 2009-07-08 | — | — | EP | disclosed |
| EP-1165564-B1 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | IND RES LTD (NZ) | 2009-03-11 | — | — | EP | disclosed |
| US-7405297-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-07-29 | — | — | US | disclosed |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-7211677-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2007-05-01 | — | — | US | disclosed |
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-7022852-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2006-04-04 | — | — | US | disclosed |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6693193-B1 | COUPLING AN N- AND O-PROTECTED 2,3-DIHYDROXY-PYRROLIDINE TO THE 2-POSITION AND DEPROTECTING | INDUSTRIAL RESEARCH LIMITED (NZ) | 2004-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | UGT1A3, AGL, PNP | DGAT1 3582/4885 |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | XDH, PNP, AGL | DGAT1 3343/4885 |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | PNP, UGT1A3, AGL | DGAT1 3467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.